RIXIMYO

This brand name is authorized in Austria, Australia, Brazil, Canada, Estonia, France, Croatia, Ireland, Italy, Lithuania, New Zealand, Poland

Active ingredients

The drug RIXIMYO contains one active pharmaceutical ingredient (API):

1 Rituximab UNII 4F4X42SYQ6 - RITUXIMAB

Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas. Read about Rituximab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FA01	Rituximab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FA CD20 (Clusters of Differentiation 20) inhibitors
Discover more medicines within L01FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10179R, 10193L, 10576P, 10583B, 10591K, 10593M, 11790M, 11800C, 11804G, 11805H, 11810N, 11813R, 11935E, 11936F, 4613T, 4614W, 4615X, 7257Y, 7258B, 7259C, 9544H, 9611W
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 511519060070807, 511519060070907
Country: CA	Health Products and Food Branch	Identifier(s): 02498316
Country: EE	Ravimiamet	Identifier(s): 1748347, 1748358, 1748369, 1748370
Country: FR	Base de données publique des médicaments	Identifier(s): 60981675, 67291239
Country: IT	Agenzia del Farmaco	Identifier(s): 045449016, 045449028, 045449030, 045449042
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1083157, 1083158, 1083159, 1083160
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 19617
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100391693, 100391701